Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

China flag China · Delayed Price · Currency is CNY
41.80
+1.52 (3.77%)
Jul 16, 2025, 3:11 PM CST
623.18%
Market Cap19.97B
Revenue (ttm)293.05M
Net Income (ttm)-143.41M
Shares Out477.77M
EPS (ttm)-0.30
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume20,002,424
Average Volume31,352,756
Open39.60
Previous Close40.28
Day's Range39.60 - 42.00
52-Week Range5.55 - 47.96
Beta1.10
RSI60.77
Earnings DateAug 26, 2025

About SHE:300204

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Troponium Chloride Capsules, Gliclazide extended-release ta... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 492
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300204
Full Company Profile

Financial Performance

In 2024, SHE:300204's revenue was 324.82 million, a decrease of -10.81% compared to the previous year's 364.18 million. Losses were -144.84 million, -63.69% less than in 2023.

Financial Statements

News

There is no news available yet.